Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Lymphoma 6Small Cell Lung Carcinoma 5Breast Neoplasms 4Ovarian Neoplasms 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Mantle-Cell 2Burkitt Lymphoma 2Advanced Solid Tumors 2Advanced Nonhematologic Malignancies 2Advanced Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Immunoblastic Lymphadenopathy 1Fallopian Tube Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Paclitaxel 47Carboplatin 38liposomal doxorubicin 25Bevacizumab 23Gemcitabine 18Topotecan 15pembrolizumab 14mirvetuximab soravtansine 11rucaparib 8niraparib 7Cisplatin 71-dodecylpyridoxal 7trebananib 6Drug Therapy 6130-nm albumin-bound paclitaxel 6Nivolumab 5Cyclophosphamide 5cemiplimab 4sarilumab 3relacorilant 3pazopanib 3oregovomab 3olaparib 3Doxorubicin 3Docetaxel 3Albumin-Bound Paclitaxel 3tocilizumab 2seribantumab 2phenoxodiol 2pegfilgrastim 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Fallopian Tube Neoplasms × MLN 8237 × Clear all
NCT01091428 2018-06-04

Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer

Takeda

Phase 2 Completed
191 enrolled 39 charts
BreastGynecologic

Breast Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡